UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Clinical therapeutics, ISSN 0149-2918, 2008, Volume 30, Issue 8, pp. 1426 - 1447
Internal Medicine | Medical Education | dual-receptor inhibitor | GW572016 | lapatinib | pharmacokinetics | clinical trials | adverse events | HER2 | EGFR | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Area Under Curve | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme System - metabolism | Half-Life | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Clinical Trials, Phase III as Topic | Drug Interactions | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Quinazolines - pharmacology | Clinical Trials, Phase II as Topic | Antimitotic agents | Tyrosine | Care and treatment | Epidermal growth factor | Phenols | Metastasis | Phosphotransferases | Cancer | Index Medicus
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2007, Volume 6, Issue 2, pp. 667 - 674
Herceptin | ErbB-2 | IGF-I receptor | GW572016 | αIR3 | Life Sciences & Biomedicine | Oncology | Science & Technology | Receptor, IGF Type 1 - metabolism | Immunoprecipitation | Signal Transduction | Apoptosis - drug effects | Antibodies, Monoclonal - pharmacology | Humans | Drug Resistance, Neoplasm | Immunoblotting | Cell Line, Tumor - drug effects | Breast Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized | Breast Neoplasms - pathology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Receptor, ErbB-2 - antagonists & inhibitors | Cell Cycle - drug effects | Quinazolines - pharmacology | Insulin-Like Growth Factor I - metabolism | Trastuzumab | Index Medicus
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2009, Volume 31, Issue 2, pp. 2332 - 2348
Internal Medicine | Medical Education | ErbB2 | ErbB1 | GW572016 | dual tyrosine kinase inhibitor | lapatinib | HER2 | Tykerb | EGFR | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Protein Kinase Inhibitors - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Humans | Quinazolines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Protein Kinase Inhibitors - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Quinazolines - pharmacology | Breast Neoplasms - drug therapy | Index Medicus
Journal Article
Annual review of medicine, ISSN 0066-4219, 2004, Volume 55, Issue 1, pp. 433 - 457
Gefitinib | GW572016 | Erlotinib CI-1033 | EGFR | Epidermal growth factor receptor | EKB-569 | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neoplasms - therapy | Humans | Receptor Protein-Tyrosine Kinases - physiology | Antibodies, Monoclonal - physiology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Signal Transduction - physiology | Neoplasms - physiopathology | Research | Therapeutics | Homeopathy | Materia medica and therapeutics | Proteins | Medical research | Drug therapy | Cancer | Index Medicus
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 11/2006, Volume 11, Issue 10, pp. 1047 - 1057
GW572016 | ErbB‐1 | ErbB‐2 | Breast cancer | Lapatinib | HER‐2 | Dual tyrosine kinase inhibitor | EGFR | ErbB-2 | ErbB-1 | HER-2 | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Clinical Trials as Topic | Protein Kinase Inhibitors - adverse effects | Receptor Protein-Tyrosine Kinases - metabolism | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Breast Neoplasms - enzymology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Chemotherapy, Adjuvant | Heart Diseases - chemically induced | Trastuzumab | Index Medicus
Journal Article
The Annals of pharmacotherapy, ISSN 1060-0280, 02/2006, Volume 40, Issue 2, pp. 261 - 269
Breast cancer | Lapatinib | HER2 | GW572016 | Dual tyrosine kinase inhibitor | EGFR | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Tumors | Protein Kinase Inhibitors - pharmacokinetics | Humans | Neoplasms - enzymology | Quinazolines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Protein Kinase Inhibitors - adverse effects | PubMed | Neoplasms - drug therapy | Animals | Antineoplastic Agents - adverse effects | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Drug Design | Quinazolines - adverse effects | Antineoplastic Agents - pharmacokinetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 6/2007, Volume 18, Issue suppl_6, pp. vi26 - vi30
Breast cancer | Lapatinib | HER2 | GW572016 | Dual tyrosine kinase inhibitor | EGFR | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Humans | Quinazolines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Animals | Antineoplastic Agents - adverse effects | Quinazolines - therapeutic use | Quinazolines - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Quinazolines - pharmacology | Index Medicus
Journal Article
Investigational new drugs, ISSN 0167-6997, 1/2005, Volume 23, Issue 1, pp. 39 - 49
Medicine & Public Health | GW572016 | signal transduction | Oncology | phase I | tyrosine kinase inhibitor | Pharmacology/Toxicology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Double-Blind Method | Administration, Oral | Area Under Curve | Humans | Middle Aged | Quinazolines - pharmacokinetics | Male | Cross-Over Studies | Maximum Tolerated Dose | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Safety | Antimitotic agents | Tyrosine | Complications and side effects | Dosage and administration | Research | Antineoplastic agents | Health aspects | Index Medicus
Journal Article
9.
Full Text
A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer
Therapeutics and clinical risk management, ISSN 1176-6336, 2007, Volume 3, Issue 4, pp. 665 - 673
Journal Article
Women's health (London, England), ISSN 1745-5057, 06/2015, Volume 11, Issue 3, pp. 281 - 294
letrozole | trastuzumab | capecitabine | GW572016 | ERBB2 | metastatic breast cancer | lapatinib | HER-2 | Breast Neoplasms - genetics | Women's Health | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | United States | Humans | Postmenopause | Female | Antineoplastic Agents - therapeutic use | Receptor, ErbB-2 | Breast Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Dosage and administration | Enzyme inhibitors | Antineoplastic agents | Proteins | Signal transduction | Chemotherapy | Womens health | Medical prognosis | Ligands | Breast cancer | Metastasis | Kinases | Cancer therapies | Binding sites | Tumors | Index Medicus
Journal Article